Accordingly, in patients with type 2 diabetes and established HF with reduced ejection fraction and/or known cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended to reduce risk of worsening HF and cardiovascular death (American Diabetes Association Professional Practice Committee et al., 2022). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.